Parnassus Investments LLC Sells 7,779 Shares of IQVIA Holdings Inc. $IQV

Parnassus Investments LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,552 shares of the medical research company’s stock after selling 7,779 shares during the period. Parnassus Investments LLC’s holdings in IQVIA were worth $37,903,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Artisan Partners Limited Partnership bought a new position in shares of IQVIA in the second quarter valued at about $515,772,000. Norges Bank bought a new position in shares of IQVIA in the second quarter worth about $270,160,000. AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC increased its holdings in shares of IQVIA by 15,755.2% in the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after purchasing an additional 774,681 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on IQV. Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and boosted their price target for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, Citigroup lifted their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Stock Performance

Shares of IQV stock opened at $242.70 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.05. The company’s 50 day moving average price is $224.37 and its two-hundred day moving average price is $200.19. The company has a market capitalization of $41.33 billion, a P/E ratio of 33.29, a price-to-earnings-growth ratio of 2.47 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.